Welcome to the Mood Center
At The Mood Center in Columbia, MD, we specialize in delivering expert mental health services grounded in compassion and proven results. Our dedicated team offers advanced treatments, including IV Ketamine and IM Ketamine, and SPRAVATO® (esketamine), to address conditions such as depression, anxiety, PTSD, and chronic pain. By combining cutting-edge therapies with personalized care, we aim to provide lasting relief and enhance the well-being of our patients.
Ketamine therapy in Columbia, MD, is a fast-acting option for individuals with treatment-resistant depression, anxiety, PTSD, and chronic pain. Delivered intravenously (IV) or intramuscularly (IM), ketamine works by resetting brain pathways that regulate mood. At the Mood Center, we provide a calm, medically supervised environment to ensure safety and comfort during each session.
SPRAVATO® is an FDA-approved nasal spray for adults with major depressive disorder who haven’t responded to other treatments. Administered under professional supervision, SPRAVATO® offers rapid relief by targeting brain receptors differently than traditional antidepressants. Our team ensures each treatment is carefully monitored to support optimal results.
IV/IM Ketamine and SPRAVATO® (esketamine) offer a powerful new approach to treating mood disorders when traditional methods fall short. Unlike typical antidepressants, which can take weeks to work, these treatments act rapidly by targeting the brain’s glutamate system—a key player in mood regulation, stress response, and neuroplasticity.
Both therapies stimulate areas of the brain involved in emotion and cognition, helping to restore healthier neural connections. This can lead to fast, lasting relief from conditions like depression, anxiety, PTSD, and more. Many patients report a noticeable shift in mood, clarity, and energy after just a few sessions.
At the Mood Center, we administer these treatments in a calm, supportive setting under the supervision of experienced professionals, ensuring safety and comfort every step of the way.
SPRAVATO® is designed for adults with treatment-resistant depression—people who haven’t found relief with traditional antidepressants. It works differently, targeting the brain’s glutamate system to help reset mood pathways and deliver results faster.
Real Relief, Real Stories
Many patients report feeling better within hours or days of treatment. For some, SPRAVATO® has made it possible to return to daily life, reconnect with loved ones, and rediscover a sense of hope.
Monitored, Trusted, FDA-Approved
SPRAVATO® is given under medical supervision in certified clinics to ensure safety and support. Backed by clinical studies and FDA approval, it’s changing the way we treat depression—one life at a time.
Answer:
IV (intravenous) ketamine therapy involves administering ketamine directly into the bloodstream via a vein, allowing for precise dosing and rapid onset of effects.
IM (intramuscular) ketamine is injected into a large muscle, such as the thigh or shoulder, and although absorption is slightly slower than IV, it still provides effective therapeutic outcomes.
IV allows for continuous monitoring and dose adjustments during the session, while IM is simpler to administer and often preferred for its convenience and lower equipment requirements.
Answer:
Both IV and IM ketamine are effective in treating mood disorders like depression and anxiety. Clinical studies suggest that IV ketamine has slightly more robust and faster-acting results due to the controlled dosing and steady delivery.
However, IM ketamine has shown comparable success in many cases and is a valid alternative, especially for patients who are needle-averse or prefer a less clinical setting. The choice between the two often comes down to patient preference, clinic protocol, and the nature of the individual’s condition.
Answer:
An IV ketamine infusion typically lasts between 40 to 60 minutes, followed by a recovery period.
IM ketamine sessions are slightly shorter in administration—usually taking 15 to 20 minutes to inject—but patients still need monitoring during the experience and afterward, bringing the total time commitment to about 60 to 90 minutes for both methods.
The overall duration can vary based on dosage, patient response, and clinic procedures.
Answer:
During both IV and IM ketamine therapy, patients may experience a sense of detachment from their body or surroundings, known as dissociation.
Other common effects include visual or auditory distortions, altered perception of time, and deep introspective thoughts.
These effects are temporary and typically fade as the drug metabolizes. Clinics provide a calming environment with monitoring to ensure safety and comfort throughout the experience.
Ketamine therapy is generally well-tolerated, but like any treatment, it carries potential side effects. Common short-term effects include nausea, dizziness, increased heart rate or blood pressure, blurred vision, and mild confusion.
Serious risks are rare but may include hallucinations, anxiety during the experience, or an adverse reaction to anesthesia-like effects.
Long-term or frequent use, particularly at high doses or without medical supervision, could lead to bladder or liver issues.
It’s critical that ketamine therapy be administered by trained professionals in a controlled clinical setting
Answer:
SPRAVATO® is the brand name for esketamine, a prescription nasal spray derived from ketamine. It’s FDA-approved for treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior.
Unlike traditional antidepressants, SPRAVATO® works on the glutamate system in the brain, helping to restore synaptic connections and balance mood-related neurotransmitters more rapidly. It is always administered under medical supervision in a certified treatment center.
Answer:
SPRAVATO® offers a fast-acting alternative for those who haven’t responded to standard antidepressants. Unlike oral medications, which can take weeks to show effects, SPRAVATO® can begin working within hours to days.
Compared to IV ketamine, SPRAVATO® is self-administered intranasally under clinical observation, with fixed dosing schedules. It’s specifically FDA-approved and regulated, making it more widely covered by insurance, while IV ketamine remains off-label for mental health treatment.
Answer:
A SPRAVATO® session takes place in a certified clinic. After checking in, patients self-administer the nasal spray under the guidance of medical staff. They then remain under observation for at least two hours due to potential side effects like dizziness, dissociation, or increased blood pressure.
Treatments typically begin twice a week for the first month, followed by weekly or biweekly maintenance sessions, depending on individual response and clinical judgment.
Answer:
Common side effects of SPRAVATO® include dissociation (feeling disconnected from reality), dizziness, nausea, drowsiness, increased blood pressure, and headache. These symptoms usually subside within the monitored recovery period.
Because of these effects, patients are not allowed to drive or operate machinery until the next day. The clinic monitors vitals and provides support during the visit to ensure patient safety and comfort.
Yes, many insurance providers do cover SPRAVATO® treatment, especially for patients diagnosed with treatment-resistant depression or major depressive disorder with suicidal thoughts. However, coverage can vary depending on your specific plan and insurance company. Our team will work directly with your insurance provider to verify your benefits and obtain any necessary prior authorizations.
To get started with SPRAVATO® treatment, you’ll typically begin with a consultation and comprehensive mental health assessment. If SPRAVATO® is deemed appropriate, we’ll guide you through the enrollment process, schedule your sessions, and help you navigate the paperwork and insurance steps to ensure a smooth start to care.
